A Phase 3 interventional study of Apixaban and Acetylsalicylic acid in Atrial Fibrillation, sponsored by Bristol-Myers Squibb. Completed at 503 sites in 36 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-06-15.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.
Among the 31 studies testing apixaban in Atrial Fibrillation, this one is the 4th largest by enrollment, is the only one that started in 2007, is one of 12 in phase 3, and was the 2nd registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
VA Office of Research and Development · Sites in United States
Ages 22+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,421 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 586 across the 31 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 31 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
33 studies in Atrial Fibrillation by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 30 finished, 4 (13%) have results posted.
Among the 33 studies in Atrial Fibrillation by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 3, and was the 3rd registered.
Bristol-Myers Squibb’s Atrial Fibrillation studies by the year they started, since 2006.
2 of the studies testing apixaban in Atrial Fibrillation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies testing apixaban in Atrial Fibrillation, from their registry updates:
Among Bristol-Myers Squibb’s 33 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation. The safety of this treatment will also be studied.
An optional Long-term Open-label Extension Phase of treatment with apixaban will be provided for qualifying participants following the conclusion of the double-blind phase
Key Inclusion Criteria:
At least 1 of the following risk factors for stroke:
Not currently receiving vitamin K antagonist therapy for 1 of the following reasons:
Key Exclusion Criteria:
Patients with serious bleeding in the last 6 months or at high risk for bleeding, including but not limited to those with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Apixaban
Drug: Acetylsalicylic acid
Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
Also known as: BMS-562247
Tablets, oral, 81-324 mg, once daily, up to 156 weeks
Event Rate of Stroke/Systemic Embolism During the Intended-treatment Period
Event rate=percent of participants with an event divided by the total participants in the arm. Intended-treatment period=date of randomization to the efficacy cutoff date, which was to be the date on which at least 226 unrefuted original primary efficacy events occurred (date revised to May 28, 2010 following cessation of study for superior efficacy.)
Time frame: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
Event Rate for the Composite of Stroke of Any Type, Systemic Embolism, Myocardial Infarction, or Vascular Death During the Double-blind Treatment Period
Event rate=percent of participants with an event divided by the total participants in the arm.
Time frame: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
Event Rate of All-cause Death; Net Clinical Benefit-Composite of Stroke, Systemic Embolism, Myocardial Infarction, Vascular Death, and Major Bleeding; and Vascular Death
Event rate=percent of participants with an event divided by the total participants in the arm.
Time frame: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
Event Rates for Major Bleeding, Major or Clinically Relevant Nonmajor (CNRM) Bleeding, and All Bleeding in the Double-blind Period
Event rate=percent of participants with an event divided by the total participants in the arm.
Time frame: First dose of study drug (Day 1) to the earlier of a patient's discontinuation of double-blind study drug or the attainment of at least 226 primary efficacy events up to May 28, 2010
Rate of Unrefuted Bleeding From First Dose of Double-blind Study Drug to First Occurence of Unrefuted Bleeding During the Double-blind Treatment Period
Event rate=percent of participants with an event divided by the total participants in the arm.
Time frame: Day 1 to first bleeding event up to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs), Bleeding AEs, Discontinuations Due to AEs, and Death as Outcome
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality
BL=baseline, LLN=lower limit of normal, ULN=upper limit of normal. Hemoglobin (g/dL), low: BL\>2 or value ≤8; hematocrit(%), low: \<0.75\*BL; erythrocytes (\*10\^6 cells/μL), low: \<0.75\*BL; platelet count (\*10\^9 cells/L),low: \<100\*10\^9 cells/L; leukocytes (\*10\^3 cells/μL), low if \<0.8\*BL and BL\<LLN or \<LLN and BL \>ULN or \<0.75\*LLN when BL is missing or LLN ≤BL≤ ULN, high if \>1.2\*BL and BL\>ULN or \>ULN when BL and BL\<LLN or \>1.25\*ULN when BL is missing or LLN≤BL≤ULN; neutrophils (absolute), low: \<1.0\*10\^3 cells/μL; eosinophils (absolute), high: \>0.750\*10\^3 cells/μL; basophils (absolute), high: \>0.4\*10\^3 cells/μL; monocytes (absolute), high: 2\*10\^3 cells/μL; lymphocytes (absolute), low if \<0.75\*10\^3 cells/μL, high if \>7.50\*10\^3 cells/μL; ALP (U/L), high: 2\*ULN; AST (U/L), high: 3\*ULN; AST (U/L), high: 3\*ULN; bilirubin, total (mg/dL), high: \>2\*ULN; bilirubin, direct (mg/dL), high: 1.5\*ULN; BUN (mg/dL), high:\>2\*ULN; creatinine (mg/dL), high: \>1.5\*ULN.
Time frame: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality (Continued)
LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Sodium, serum (mEq/L):low if \<0.95\*BL and BL\<LLN or \<LLN and BL\>ULN or \<0.95\*LLN when BL missing or LLN ≤BL≤ULN, high if \>1.05\*BL and BL\>ULN or \>ULN and BL\<LLN or \>1.05\*ULN when BL missing or LLN≤BL≤ULN; potassium(mEq/L):low if \<0.90\*BL and BL\<LLN or \<LLN and BL\>ULN or \<0.90\*LLN if BL missing or LLN≤BL≤ULN, high if \>1.10\*BL and BL\>ULN or\>ULN and BL\<LLN or \>1.10\*ULN when BL missing or LLN≤BL≤ULN; chloride(mEq/L):low if \<0.90\*BL and BL\<LLN or \<LLN and BL\>ULN or \<0.90\*LLN if BL missing or LLN≤BL ≤ULN, high if \>1.10\*BL and BL\>ULN or \>ULN and BL\<LLN or \>1.10\* ULN if BL missing or LLN≤BL≤ULN; calcium(mg/dL):low if \<0.75\*BL and BL\<LLN or \<LLN and BL\>ULN or \<0.80\*LLN if BL missing or LLN≤BL≤ULN, high if \>1.25\*BL and BL\>ULN or \>ULN if BL\<LLN or \>1.20\*ULN if BL missing or LLN≤BL≤ULN ; bicarbonate(mEq/L):low if \<0.75\*BL when BL\<LLN or \<LLN when BL\>ULN or \<0.75\*LLN if BL missing or LLN≤BL≤ULN, high if \>1.25\*BL when BL\>ULN or \>ULN
Time frame: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality (Continued)
ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Creatine kinase (U/L), high:\>5\*ULN; protein, total(g/L):low if \<0.90\*BL when BL\<LLN or \<LLN when B \>ULN or \<0.90\*LLN when BL is missing or LLN≤BL≤ULN, high if \>1.10\*BL if BL\>ULN or \>ULN when BL\<LLN or \>1.10\*ULN if BL missing or LLN≤BL≤ULN.Protein,total(g/L): low if \<0.90\*BL if BL\<LLN or \<LLN if BL\>ULN or \<0.90\*LLN if BL missing or LLN≤BL≤ULN, high if \>1.10\*BL if BL\>ULN or \>ULN if BL\<LLN or \>1.10\*ULN if BL or LLN≤BL≤ULN; glucose, serum fasting (mg/dL): low if \<0.8\*BL if BL\<LLN or \<LLN when BL\>ULN or \<0.8\*LLN when BL missing or LLN≤BL≤ULN, high if \>2\*BL when BL\>ULN or \>ULN when BL\<LLN or \>1.5\*ULN if BL missing or LLN≤BL≤ULN; uric acid (mg/dL), high: \>2\*BL and BL\>ULN or\>1.5\*ULN when BL missing or BL≤ULN; glucose, urine, high; protein, urine, high; blood, urine, high; leukocyte esterase, urine, high; RBC count, urine (Hpf), high; WBC count, urine (Hpf), high: ≥2 if BL=missing,=0 or =0.5 or if ≥3 if BL=1, or if ≥4 and BL≥2.
Time frame: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Milestone | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Open Label Apixaban |
|---|---|---|---|
| Started | 2807 | 2791 | 0 |
| Received treatment | 2798 | 2708 | 0 |
| Completed | 2249 | 2142 | 0 |
| Not completed | 558 | 649 | 0 |
| Withdrew: >=1 reason assigned per patient | 558 | 649 | 0 |
| Milestone | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Open Label Apixaban |
|---|---|---|---|
| Started | 0 | 0 | 3275 |
| Completed | 0 | 0 | 2264 |
| Not completed | 0 | 0 | 1011 |
| Withdrew: >=1 reason assigned per patient | 0 | 0 | 1011 |
Event rate=percent of participants with an event divided by the total participants in the arm. Intended-treatment period=date of randomization to the efficacy cutoff date, which was to be the date on which at least 226 unrefuted original primary efficacy events occurred (date revised to May 28, 2010 following cessation of study for superior efficacy.)
| Percentage of events | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily |
|---|---|---|
| Event Rate of Stroke/Systemic Embolism During the Intended-treatment Period | 1.62 | 3.63 |
Event rate=percent of participants with an event divided by the total participants in the arm.
| Percentage of events per year | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily |
|---|---|---|
| Event Rate for the Composite of Stroke of Any Type, Systemic Embolism, Myocardial Infarction, or Vascular Death During the Double-blind Treatment Period | 4.21 | 6.35 |
Event rate=percent of participants with an event divided by the total participants in the arm.
| Percentage of events per year | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily |
|---|---|---|
| All-cause death (n=111, 140) | 3.51 | 4.42 |
| Net clinical benefit (n=163, 220) | 5.23 | 7.13 |
| Vascular death (n=84, 96) | 2.65 | 3.03 |
Event rate=percent of participants with an event divided by the total participants in the arm.
| Percentage of events per year | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily |
|---|---|---|
| Major bleeding | 1.41 | 0.92 |
| Major or CRNM bleeding | 4.46 | 3.24 |
| All bleeding | 10.85 | 8.32 |
Event rate=percent of participants with an event divided by the total participants in the arm.
| Percentage of events per year | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily |
|---|---|---|
| Rate of Unrefuted Bleeding From First Dose of Double-blind Study Drug to First Occurence of Unrefuted Bleeding During the Double-blind Treatment Period | 10.85 | 8.32 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| Participants | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily |
|---|---|---|
| AEs | 1833 | 1925 |
| SAEs | 657 | 804 |
| Bleeding AEs | 281 | 259 |
| Discontinuations due to AE | 266 | 362 |
| Deaths | 91 | 115 |
BL=baseline, LLN=lower limit of normal, ULN=upper limit of normal. Hemoglobin (g/dL), low: BL\>2 or value ≤8; hematocrit(%), low: \<0.75\*BL; erythrocytes (\*10\^6 cells/μL), low: \<0.75\*BL; platelet count (\*10\^9 cells/L),low: \<100\*10\^9 cells/L; leukocytes (\*10\^3 cells/μL), low if \<0.8\*BL and BL\<LLN or \<LLN and BL \>ULN or \<0.75\*LLN when BL is missing or LLN ≤BL≤ ULN, high if \>1.2\*BL and BL\>ULN or \>ULN when BL and BL\<LLN or \>1.25\*ULN when BL is missing or LLN≤BL≤ULN; neutrophils (absolute), low: \<1.0\*10\^3 cells/μL; eosinophils (absolute), high: \>0.750\*10\^3 cells/μL; basophils (absolute), high: \>0.4\*10\^3 cells/μL; monocytes (absolute), high: 2\*10\^3 cells/μL; lymphocytes (absolute), low if \<0.75\*10\^3 cells/μL, high if \>7.50\*10\^3 cells/μL; ALP (U/L), high: 2\*ULN; AST (U/L), high: 3\*ULN; AST (U/L), high: 3\*ULN; bilirubin, total (mg/dL), high: \>2\*ULN; bilirubin, direct (mg/dL), high: 1.5\*ULN; BUN (mg/dL), high:\>2\*ULN; creatinine (mg/dL), high: \>1.5\*ULN.
| Participants | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily |
|---|---|---|
| Hemoglobin, low (n=1956, 1893) | 131 | 120 |
| Hemoglobin, high (n=1956, 1893) | 0 | 0 |
| Hematocrit, low (n=1728, 1687) | 13 | 9 |
| Hematocrit, high (n=1728, 1687) | 0 | 0 |
| Erythrocytes, low (n=1728, 1687) | 12 | 12 |
| Erythrocytes, high (n=1728, 1687) | 0 | 0 |
| Platelet count, low (n=2148, 2098) | 7 | 10 |
| Platelet count, high (n=2148, 2098) | 0 | 0 |
| Leukocytes, low (n=1738, 1698) | 12 | 14 |
| Leukocytes, high (n=1738, 1698) | 14 | 18 |
| Neutrophils (absolute), low (n=2170, 2138) | 2 | 1 |
| Neutrophils (absolute), high (n=2170, 2138) | 0 | 0 |
| Eosinophils (absolute), low (n=2170, 2138) | 0 | 0 |
| Eosinophils (absolute), high (n=2170, 2138) | 48 | 68 |
| Basophils (absolute), low (n=2170, 2138) | 0 | 0 |
| Basophils (absolute), high (n=2170, 2138) | 0 | 0 |
| Monocytes (absolute), low (n=2170, 2138) | 0 | 0 |
| Monocytes (absolute), high (n=2170, 2138) | 0 | 2 |
| Lymphocytes (absolute), low (n=2170, 2138) | 52 | 62 |
| Lymphocytes (absolute), high (n=2170, 2138) | 4 | 5 |
| Alkaline phosphatase (ALP), low (n=2781, 2758) | 0 | 0 |
| ALP, high (n=2781, 2758) | 34 | 27 |
| Aspartate phosphatase (AST), low (n=2779, 2753) | 0 | 0 |
| AST, high (n=2779, 2753) | 28 | 33 |
| Alanine aminotransferase (ALT), low (n=2779, 2753) | 0 | 0 |
| ALT, high (n=2779, 2753) | 23 | 31 |
| Bilirubin (total), low (n=2781, 2758) | 0 | 0 |
| Bilirubin (total), high (n=2781, 2758) | 30 | 43 |
| Bilirubin (direct), low (n=2773, 2750) | 0 | 0 |
| Bilirubin (direct), high (n=2773, 2750) | 241 | 248 |
| Blood urea nitrogen (BUN), low (n=2201, 2172) | 0 | 0 |
| BUN, high (n=2201, 2172) | 42 | 50 |
| Creatinine, low (n=2209, 2178) | 0 | 0 |
| Creatinine, high (n=2209, 2178) | 67 | 71 |
LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Sodium, serum (mEq/L):low if \<0.95\*BL and BL\<LLN or \<LLN and BL\>ULN or \<0.95\*LLN when BL missing or LLN ≤BL≤ULN, high if \>1.05\*BL and BL\>ULN or \>ULN and BL\<LLN or \>1.05\*ULN when BL missing or LLN≤BL≤ULN; potassium(mEq/L):low if \<0.90\*BL and BL\<LLN or \<LLN and BL\>ULN or \<0.90\*LLN if BL missing or LLN≤BL≤ULN, high if \>1.10\*BL and BL\>ULN or\>ULN and BL\<LLN or \>1.10\*ULN when BL missing or LLN≤BL≤ULN; chloride(mEq/L):low if \<0.90\*BL and BL\<LLN or \<LLN and BL\>ULN or \<0.90\*LLN if BL missing or LLN≤BL ≤ULN, high if \>1.10\*BL and BL\>ULN or \>ULN and BL\<LLN or \>1.10\* ULN if BL missing or LLN≤BL≤ULN; calcium(mg/dL):low if \<0.75\*BL and BL\<LLN or \<LLN and BL\>ULN or \<0.80\*LLN if BL missing or LLN≤BL≤ULN, high if \>1.25\*BL and BL\>ULN or \>ULN if BL\<LLN or \>1.20\*ULN if BL missing or LLN≤BL≤ULN ; bicarbonate(mEq/L):low if \<0.75\*BL when BL\<LLN or \<LLN when BL\>ULN or \<0.75\*LLN if BL missing or LLN≤BL≤ULN, high if \>1.25\*BL when BL\>ULN or \>ULN
| Participants | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily |
|---|---|---|
| Sodium (serum), low (n=1768, 1740) | 2 | 6 |
| Sodium (serum), high (n=1768, 1740) | 1 | 2 |
| Potassium (serum), low (n=1763, 1737) | 6 | 8 |
| Potassium (serum), high (n=1763, 1737) | 20 | 28 |
| Chloride (serum), low (n=1768, 1740) | 0 | 3 |
| Chloride (serum), high (n=1768, 1740) | 0 | 1 |
| Calcium (total), low (n=106, 109) | 0 | 0 |
| Calcium (total), high (n=106, 109) | 0 | 0 |
| Bicarbonate, low (n=1664, 1619) | 0 | 0 |
| Bicarbonate, high (n=1664, 1619) | 0 | 0 |
ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Creatine kinase (U/L), high:\>5\*ULN; protein, total(g/L):low if \<0.90\*BL when BL\<LLN or \<LLN when B \>ULN or \<0.90\*LLN when BL is missing or LLN≤BL≤ULN, high if \>1.10\*BL if BL\>ULN or \>ULN when BL\<LLN or \>1.10\*ULN if BL missing or LLN≤BL≤ULN.Protein,total(g/L): low if \<0.90\*BL if BL\<LLN or \<LLN if BL\>ULN or \<0.90\*LLN if BL missing or LLN≤BL≤ULN, high if \>1.10\*BL if BL\>ULN or \>ULN if BL\<LLN or \>1.10\*ULN if BL or LLN≤BL≤ULN; glucose, serum fasting (mg/dL): low if \<0.8\*BL if BL\<LLN or \<LLN when BL\>ULN or \<0.8\*LLN when BL missing or LLN≤BL≤ULN, high if \>2\*BL when BL\>ULN or \>ULN when BL\<LLN or \>1.5\*ULN if BL missing or LLN≤BL≤ULN; uric acid (mg/dL), high: \>2\*BL and BL\>ULN or\>1.5\*ULN when BL missing or BL≤ULN; glucose, urine, high; protein, urine, high; blood, urine, high; leukocyte esterase, urine, high; RBC count, urine (Hpf), high; WBC count, urine (Hpf), high: ≥2 if BL=missing,=0 or =0.5 or if ≥3 if BL=1, or if ≥4 and BL≥2.
| Participants | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily |
|---|---|---|
| Creatine kinase, low (n=2780, 2758) | 0 | 0 |
| Creatine kinase, high (n=2780, 2758) | 13 | 25 |
| Protein (total), low (n=103, 109) | 0 | 0 |
| Protein (total), high (n=103, 109) | 0 | 0 |
| Uric acid, low (n=386, 390) | 0 | 0 |
| Uric acid, high (n=386, 390) | 1 | 0 |
| Glucose (urine), low (n=2, 3) | 0 | 0 |
| Glucose (urine), high (n=2, 3) | 0 | 1 |
| Protein (urine), low (n=3, 5) | 0 | 0 |
| Protein (urine), high (n=3, 5) | 1 | 1 |
| Blood (urine), low (n=3, 5) | 0 | 0 |
| Blood (urine), high (n=3, 5) | 1 | 0 |
| Leukocyte esterase (urine), low (n=3,5) | 0 | 0 |
| Leukocyte esterase (urine), high (n=3,5) | 0 | 0 |
| Red blood cells (RBC) (urine), low (n=2,2) | 0 | 0 |
| RBC (urine), high (n=2,2) | 1 | 0 |
| White blood cells (urine), low (n=2,2) | 0 | 0 |
| WBC (urine), high (n=2,2) | 0 | 0 |
Collected over From first dose to last dose plus 30 days (assessed up to May 2017, approximately 95 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 111/2,798 (4%) | 657/2,798 (23.5%) | 207/2,798 (7.4%) |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 140/2,780 (5%) | 804/2,780 (28.9%) | 267/2,780 (9.6%) |
| Open Label Apixaban | 286/3,275 (8.7%) | 1,228/3,275 (37.5%) | 180/3,275 (5.5%) |
| Event | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Open Label Apixaban |
|---|---|---|---|
| Cardiac failureCardiac disorders | 60/2798 | 76/2780 | 116/3275 |
| Atrial fibrillationCardiac disorders | 72/2798 | 70/2780 | 113/3275 |
| PneumoniaInfections and infestations | 37/2798 | 55/2780 | 99/3275 |
| Ischaemic strokeNervous system disorders | 19/2798 | 46/2780 | 22/3275 |
| Cardiac failure congestiveCardiac disorders | 39/2798 | 28/2780 | 53/3275 |
| Cerebrovascular accidentNervous system disorders | 16/2798 | 40/2780 | 15/3275 |
| DeathGeneral disorders | 14/2798 | 9/2780 | 38/3275 |
| Transient ischaemic attackNervous system disorders | 10/2798 | 29/2780 | 13/3275 |
| Sudden deathGeneral disorders | 9/2798 | 12/2780 | 32/3275 |
| Chest painGeneral disorders | 16/2798 | 24/2780 | 28/3275 |
| Event | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Open Label Apixaban |
|---|---|---|---|
| DizzinessNervous system disorders | 109/2798 | 144/2780 | 132/3275 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 109/2798 | 141/2780 | 164/3275 |
| Age, Continuous(years) | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Total |
|---|---|---|---|
| Mean | 69.7 ± 9.44 | 70.0 ± 9.71 | 69.9 ± 9.58 |
| Age, Customized(Participants) | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Total |
|---|---|---|---|
| < 65 years | 855 | 865 | 1720 |
| >=65 but <75 years | 1049 | 938 | 1987 |
| >=75 years | 903 | 988 | 1891 |
| Sex: Female, Male(Participants) | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Total |
|---|---|---|---|
| Female | 1147 | 1174 | 2321 |
| Male | 1660 | 1617 | 3277 |
| Race/Ethnicity, Customized(Participants) | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 6 | 12 |
| Asian | 541 | 544 | 1085 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| Black or African American | 10 | 26 | 36 |
| White | 2221 | 2178 | 4399 |
| Other | 26 | 36 | 62 |
| Number of Participants by Number of Risk Factors for Stroke(Participants) | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Total |
|---|---|---|---|
| 1 or fewer | 1085 | 1077 | 2162 |
| 2 or more | 1722 | 1714 | 3436 |
| Number of Participants With Risk Factors for Stroke(Participants) | Apixaban, 2.5 or 5 mg Twice Daily | Acetylsalicylic Acid, 81-324 mg Once Daily | Total |
|---|---|---|---|
| Age of 75 years or older | 903 | 988 | 1891 |
| Prior stroke or transient ischemic attack | 390 | 374 | 764 |
| Heart failure (NYHA class ≥2) or LVEF ≤35% | 961 | 926 | 1887 |
| Diabetes mellitus | 536 | 559 | 1095 |
| Hypertension requiring pharmacologic treatment | 2408 | 2429 | 4837 |
| Peripheral artery disease | 66 | 78 | 144 |
Showing the first 100 of 503 sites across 36 countries. Choose a country and city above to see the rest.
Ran from Aug 2007 to primary completion in Nov 2010, 38 months.
Results were first posted in Nov 2013, 2 years 11 months after primary completion. A results delay was requested in Feb 2012.
Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 38 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban